Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. Down the line, Adagene could make up to $840 million in development and commercial ...

A study from the Weizmann Institute of Science’s Immunotherapy Research Center released this week highlights the discovery of a new class of immune-activating molecules that could help the body’s ...